Jarvik Heart said today that the FDA approved an investigational device exemption trial of its miniature left ventricular assist device in patients of less than 1 year of age to 10 years.
New York City-based Jarvik said its miniature LVAD is designed to increase blood flow as the child grows. The device is roughly the size of a AA battery, Jarvik Heart said.
“We are excited about bringing this miniaturized pump design to pediatric heart failure patients after a decade of intense engineering effort,” chairman Dr. Robert Jarvik said in prepared remarks.
“We are thankful for the NHLBI program, without which this effort to provide lifesaving support for children would not have been possible. We look forward to the day when infants and children will be able to receive a fully-implantable LVAD that will enable a greatly-improved quality of life over currently-available options,” added president Peter Hinchliffe.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.